Cosmo Bio Co. Ltd. Launches New Subsidiary in the United States
Company aims to become a major supplier of reagents, instruments, software and diagnostic services to the US life-sciences market
Advertisement
Tokyo. Cosmo Bio Co. Ltd., a major Japanese supplier of reagents, instruments and software for immunology, gene engineering, tissue culture, biochemistry and clinical diagnostics today announced the launch of its new US subsidiary company, Cosmo Bio USA, Inc. The company office located at 2792 Loker Avenue, West Carlsbad, California, was selected because of its general proximity to the surrounding biotechnology industry in San Diego County and the nearby Palomar airport and hotels.
Cosmo Bio USA will offer its customers over 2,000 products and services including its Bioruptor multi-sample cell disruptor, i-MyRun HTS agarose gel electrophoresis system and a wide range of Japanese made antibodies and reagents that customers can order through the Cosmo web-site. Also the US subsidiary will focus on finding new suppliers, develop marketing support for sales and maintain business relationships with existing suppliers.
Other news from the department business & finance
These products might interest you
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous